Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06072807 · ClinicalTrials.gov registry record · Phase 4

Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

A Phase 4 study of Breast Cancer and Brain Metastases, sponsored by Weill Medical College of Cornell University.

Recruiting
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT06072807: Recruiting Phase 4 study of Breast Cancer and Brain Metastases, sponsored by Weill Medical College of Cornell University.

NCT06072807 is a Phase 4 study of Breast Cancer and Brain Metastases that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06072807, a Phase 4 study of Breast Cancer and Brain Metastases, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.

RECRUITING
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES PET/CT brain scan will be completed before this standard of care radiation treatment. Patients will be followed prospectively with clinical and MRI assessments per standard-of-care for a total of 12 months. Study Population: Patients with ER-positive breast cancer with biopsy proven or suspected new or recurrent brain metastases (based on standard of care MRI) planned for radiation treatment of brain lesions.

Primary Outcome

Mean standardized uptake value within a region of interest placed based on MRI findings of suspicious brain lesion.

Interventions

  • DIAGNOSTIC_TEST Brain Imaging with 18F-FES

Study Locations (1)

New York

  • New York-Presbyterian/Weill Cornell Medical Center - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-12-27
Est. Completion 2027-12
Phase Phase 4

What NCT06072807 shows while recruiting

NCT06072807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Brain Imaging with 18F-FES is the first listed.

NCT06072807 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06072807 about?

NCT06072807 is a clinical study titled "Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer". The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES ...

What is the current status of trial NCT06072807?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-12-27. Estimated completion is 2027-12.

What conditions does trial NCT06072807 study?

This clinical trial studies the following conditions: Breast Cancer, Brain Metastases.

What interventions are being tested in trial NCT06072807?

The interventions under investigation include: Brain Imaging with 18F-FES (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06072807?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06072807 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06072807's enrollment target sits among peer trials

20 1079th of 1224 higher than 112 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06072807, the US trial registry maintained by the National Library of Medicine. NCT06072807 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.